SCHEMBL7478159

SCHEMBL7478159

Cc1ccc(-c2cccc(NC(=O)C(C)(C)C)n2)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.45
ADORA1 P30542 2/20 0.42
GRM5 P41594 4/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
SORT1 Q99523 1/20 0.41
ABL1 P00519 1/20 0.39
GBA1 P04062 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
GRM2 Q14416 1/20 0.39
LMNA P02545 2/20 0.38
KDM1A O60341 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSA P10619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7474902 0.84 HSD17B14 (0.42) ADORA1HSD17B14ABL1MAPTMEN1
SCHEMBL7480623 0.83 ADORA1 (0.39) ADORA1HSD17B14ABL1MAPTRAB9A
SCHEMBL7477975 0.80 MAP3K5 (0.40) MAP3K5ADORA1RAB9AMEN1KMT2A
SCHEMBL8114906 0.79 ADORA1 (0.47) MAP3K5ADORA1RAB9AHDAC1HDAC2
SCHEMBL7479491 0.78 TP53 (0.40) MAP3K5ADORA1RAB9ALMNAMEN1
SCHEMBL5833360 0.77 HPGD (0.50) ADORA1ABL1MAPTRAB9ALMNA
SCHEMBL7485304 0.76 TYK2 (0.37) MAP3K5ADORA1HSD17B14MAPT
SCHEMBL8882553 0.76 MAPT (0.46) ADORA1GBA1MAPTRAB9ALMNA
SCHEMBL7666268 0.75 LMNA (0.48) ABL1MAPTRAB9ALMNAKDM1A
SCHEMBL921576 0.74 L3MBTL1 (0.54) ADORA1RAB9ALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151572-A1 PHARMACEUTICAL USES FOR NOS INHIBITORS LOWE JOHN A (US) 2002-10-17 US disclosed
EP-1007512-B1 BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS PFIZER PROD INC (US) 2002-04-03 EP disclosed
US-6362195-B1 INHIBITOR OF NITRIC OXIDE SYNTHASE; CENTRAL NERVOUS SYSTEM DISORDERS PFIZER INC. 2002-03-26 US disclosed
US-20020022642-A1 Branched alkoxy-subsituted 2-aminopyridines LOWE JOHN ADAMS (US) 2002-02-21 US disclosed
EP-1109556-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS Pfizer Products Inc. (US) 2001-06-27 EP disclosed
EP-1007512-A1 BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS Pfizer Products Inc. (US) 2000-06-14 EP disclosed
WO-2000009130-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 WO disclosed
WO-1999011620-A1 BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS PFIZER PRODUCTS INC. (US) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022642-A1 Branched alkoxy-subsituted 2-aminopyridines NOS3, NOS2, PNMT MAP3K5 1197/4885ADORA1 196/4885GRM5 101/4885
US-20020151572-A1 PHARMACEUTICAL USES FOR NOS INHIBITORS NOS1, NOS3, NOS2 MAP3K5 1935/4885ADORA1 857/4885GRM5 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.